ANEB — Anebulo Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Anebulo up on promising data for cannabinoid intoxication therapy
Brief: Anebulo Pharmaceuticals Announces Positive Topline Data For Aneb-001 From A Phase 2 Clinical Trial For Acute Cannabinoid Intoxication
Brief: Anebulo Pharmaceuticals To Announce Topline Data For Aneb-001 From An Ongoing Phase 2 Clinical Trial For Acute Cannabinoid Intoxication On Tuesday July 5, 2022
Brief: Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., As Chief Scientific Officer
Brief: Anebulo Pharmaceuticals Reports Q3 Loss Per Share Of $0.08
Brief: Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director
Brief: Anebulo Pharmaceuticals Announces Initiation Of Phase 2 Clinical Study Evaluating ANEB-001 For The Treatment Of Acute Cannabinoid Intoxication
NASDAQ RESUMED AT 02:36 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:31 PM
NASDAQ RESUMED AT 02:22 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:17 PM
NASDAQ RESUMED AT 02:05 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:00 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:01 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:10 AM
Brief: Anebulo Pharma Reports Q1 2022 Financial Results
Brief: Anebulo Pharmaceuticals Announces Issuance Of U.S. Patent Covering Use Of Aneb-001 For The Treatment Of Acute Cannabinoid Overdose
Brief: Anebulo Pharmaceuticals Reports Q4 Loss Per Share Of $1.59
Brief: Anebulo Pharmaceuticals Announces Formation Of Scientific Advisory Board, Names First Two Members